On September 27, Gilead Sciences announcedTermination of CD47 Antibody Magrolimab in TP53-Mutated Acute Myeloid Leukemia (AML) Patients: Phase III Clinical Trial ENHANCE-2. This is the second Phase III trial of the drug that Gilead has terminated.In July of this year, Gilead Sciences, Inc. halted its ENHANCE study for high-risk myelodysplastic syndrome (MDS).Gilead Sciences stated that, according to an interim independent analysis of the ENHANCE-2 study,Compared with standard treatment, this treatment is "unlikely to show survival benefit," so the decision was made to terminate it.. In fact, Gilead Sciences has conducted 3 studies on Magrolimab.Phase III ClinicalThe trials, while ENHANCE and ENHANCE-2 have now both been terminated,Currently, only the ENHANCE-3 study remains for AML patients unsuitable for intensive chemotherapy in the first-line treatment.Notably, in August this year, part of Gilead's research on the CD47 antibody Magrolimab for the treatment of acute myeloid leukemia (AML) was once halted by the FDA. At that time, the screening and enrollment of new participants under the project’s Investigational New Drug Application (IND 147229) in the U.S. and the U.S. Expanded Access Program were suspended, but the specific reason remained unclear.Magrolimab is aPotential First-in-Class Anti-CD47 ImmunotherapyThe main mechanism of action is to block the inhibitory interaction between CD47 and signal regulatory protein (SIRPα), enhancing the ability of macrophages and other phagocytes to recognize and eliminate foreign and malignant cells, thereby blocking the "don't eat me" signal sent by cancer cells.Figure 1: AboutMagrolimab（Source: Gilead Sciences Official Website)This product was acquired by Gilead Sciences in 2020 for $4.9 billion through the acquisition of Forty Seven, Inc., establishing its leading position in the CD47 target field. As a product purchased at great expense, Gilead naturally placed high hopes on it. However, things did not go as planned. After an initial period of promise, the development of Magrolimab faced numerous challenges and setbacks.Although CD47 is considered a potential treatment for blood cancer, so far it has not proven to be very effective in clinical settings. In 2020, after signing a $2 billion deal, I-Mab and its partner AbbVie decided to halt the Phase Ib trial of the former's lemzoparlimab. This week, in an effort to cut losses, AbbVie terminated the licensing and collaboration agreement with I-Mab regarding lemzoparlimab.Celgene was once considered a leader in the CD47 antibody market, but due to "lack of evidence to support further dose escalation/expansion" in the initial data for AML and MDS, it terminated the Phase I trial of CC-90002 in 2018.AlthoughThe Research on CD47 Antibody Has Been Very Rocky, butGilead Hasn’t Given Up on Magrolimab。The antibody is still being used in the ENHANCE-3 study for frontline acute myeloid leukemia patients, but the trial remains partially on clinical hold to prevent new patients from being enrolled in the program.. In addition, itsAlso used for diffuse large B-cell lymphoma and solid tumors such as triple-negative breast cancer, brain cancer, and head and neck squamous cell carcinoma.et al.'s research.Figure 1: Magrolimab Clinical Development Program Covers Ten Potential Indications (Source: Gilead Sciences Official Website)[1]Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data. Published: Sep 27, 2023 By Kate Goodwin.[2] Gilead Sciences Official Website.To promote exchange and innovation in the antibody industry,October 14-15, 2023The 6thGolden Autumn OctoberAntibody Industry Development ConferenceAs promisedTo.The conference aims to provide researchers with an interactive platform, which will help promote the further development of the antibody industry.Time:October 14-15, 2023
Location:Suzhou(Hotel Direction Notice)
Scale:600-800 people
Organizer:Biopharmaceutical Circle, Antibody Circle
Guiding Unit:Kangweixun Biotech, Sherpa Biotech,SAPA Western China Innovation Center
Conference Fee:Free FREE!(Only charge50 yuanRegistration deposit, including participation in learning sessions, tea breaks, and conference materials, is non-refundable.September 15Registration deposit increased to100First come, first served, until fully enrolled.Registration after September 20th will incur a conference fee.！
Registration Method:Scan the QR code below or click "Read Original" at the very bottom of the article → Fill out the form → Registration successful (for volunteer registration,Undertake certain work, please consider carefully, no deposit required.）！
After the organizing committee receives the registration information, they will conduct an initial screening based on the provided details and further communicate with registrants for confirmation to extend precise invitations. Those who pass the strict review will ultimately have the opportunity to join the conference WeChat group.
Schedule
More guests are still being invited.......Scan the WeChat QR code, add the editor of Yaoshikong, and those who meet the requirements can join.
Relevant WeChat groups!
Please indicate: Name + Research Direction!
